Navigation Links
The loss of a protein makes 'jump' the tumor to the lymph node
Date:3/6/2012

Metastasis is responsible for 90% of deaths in patients with cancer. Understanding the mechanisms responsible for this process is one of the top goals of cancer research. The metastatic process involves a series of steps chained where the primary tumour invades surrounding tissues and ends spreading throughout the body. Ones of the first tissues undergoing metastasis are the lymph nodes surrounding the tumour.

A study, led by the researcher at the Bellvitge Biomedical Research Institute (IDIBELL), Manel Esteller, published in the Journal of Pathology, had identified a mechanism that explains how cancer cells escape from its original site to the lymph nodes. Investigations have uncovered that metastatic tumour cells that grow in the lymph nodes of patients with melanoma and head and neck tumours lose the activity of a protein called cadherin-11.

The normal function of this protein is to act as the anchor of a ship to fix the cells in a specific position and prevent movement. Inactivation of cadherin-11 gene causes the loss of this fixation and tumour cells "jump" to neighboring organs and structures, such as lymph nodes.

The study is an example of translational and multidisciplinary research, involving basic research laboratories, the medical oncology service at the Catalan Institute of Oncology (ICO) and the Pathology Service of the Bellvitge University Hospital.

The study coordinated by the director of the Cancer Epigenetics and Biology Program at IDIBELL, ICREA researcher and professor at the University of Barcelona, Manel Esteller, also proposes that the process can be reversed because, in models in vitro and in vivo, the recovery of protein activity cadherin-11 caused a slowing of tumour growth and decreased ability to generate metastases.

This possibility needs to be studied in international clinical trials, but it is a promising starting point in studying the biology of metastasis and how to act therapeu
'/>"/>

Contact: Arantxa Mena
comunicacio@idibell.cat
IDIBELL-Bellvitge Biomedical Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Photonic crystal biosensors detect protein-DNA interactions
2. Penn biophysicists create new model for protein-cholesterol interactions in brain and muscle tissue
3. Dont forget the vitamin A when working with its carrier protein
4. Saliva proteins could help detection of oral cancer
5. The structure of the Mre11 protein bound to DNA
6. New lab manual focuses on essential methods for purifying and characterizing proteins
7. Proteins in sperm unlock understanding of male infertility says new study
8. Response to immune protein determines pathology of multiple sclerosis
9. Columbia to award 2008 Horwitz Prize to Arthur Horwich & Ulrich Hartl for cellular protein folding
10. Human protein atlas will help pinpoint disease
11. How neuronal activity leads to Alzheimers protein cleavage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... June 26, 2015 ATL Technology, LLC, a top ... specialties in single use solutions, headquartered in Springville, ... (a California corporation with locations in ... San Jose, Costa Rica ). This acquisition ... with ATL Technology,s existing facility in ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Oslo, April 7, 2010: OptiNose, a leader in ... publication in Cephalalgia of results from its ... of its novel, intranasal drug/device product for the treatment ... and 20mg doses administered intranasally using OptiNose,s bi-directional delivery ...
... to exercise, help may be on the way. That,s ... as exercise, promotes new bone growth. This opens the ... into thinking they are getting a workout. The research ... FASEB Journal ( http://www.fasebj.org ). This ...
... Calif.) African-American women have poorer survival rates ... whether they receive radiation therapy following lumpectomy or ... Martinez, assistant professor of surgery at UC Davis ... women with advanced breast cancer are less likely ...
Cached Biology News:OptiNose's novel intranasal sumatriptan product highly effective in treating migraines 2For osteoporosis patients, exercise pill one step closer to reality 2Disparities persist in outcomes for African-American women with advanced breast cancer 2
(Date:7/6/2015)... 6, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... with Novella Clinical (Novella), to conduct the ... newly diagnosed glioblastoma. Novella is a full-service, global clinical ... to mid-sized oncology companies. The ICT-107 phase 3 trial ... Europe and Canada ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... 500 companies and professional service industries alike-- typically known for its consummate professionalism-- ... honor a good cause and break from their day jobs. , "Our motto ...
(Date:7/3/2015)... , July 3, 2015  Pomerantz LLP announces that ... Biotechnology, Inc. ("Puma" or the "Company")(NYSE: PBYI ) ... in United States District Court, Central District of ... on behalf of a class consisting of all persons ... 2014 and May 13, 2015 inclusive (the "Class Period").  ...
(Date:7/2/2015)... -- Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property development ... property, today announced a litigation update. In ... Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, in the ... Virginia , the Court issued a ... claims in favor of the Defendants on the one ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2The Alexander Group Declares Their Independence with a Bit of Levity 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3
... DIEGO , March 16  Neurocrine Biosciences, Inc. (Nasdaq: ... recently completed public offering of common stock has exercised in ... common stock to cover over-allotments.  The sale of the additional ... into account the sale of the additional shares at a ...
... Shire plc (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice Letter,from Teva Pharmaceuticals USA, Inc. ("Teva") advising of ... release tablets,INTUNIV(TM). , ... , ... ...
... LONDON, ON , March 16 /PRNewswire/ ... protein therapeutic, demonstrated positive results in a pivotal proof ... model for arthritis. VT-346 achieved a statistically significant, dose ... prevented deterioration due to disease in terms of weight ...
Cached Biology Technology:Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering 2Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 2Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 3Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic 4
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... has been designed and created in order ... friendly genotyping analysis tool. We incorporated the ... into the software. Their main requirements were ... low acquisition cost. GeneMarker can perform ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
... 3D structure visualization, phylogenetic tree building, sequence ... single application. Retrieve ... and filter them in real-time Organize ... searching, filtering and sorting Provides up-to-date ...
Biology Products: